What is the Current Clinical Impact of the CYP2CTG Haplotype?

dc.creator	Ingelman-Sundberg, Magnus
dc.creator	Jukić, Marin
dc.creator	Bråten, Line Skute
dc.creator	Kringen, Marianne Kristiansen
dc.creator	Molden, Espen
dc.date.accessioned	2023-11-28T16:55:10Z
dc.date.available	2023-11-28T16:55:10Z
dc.date.issued	2024
dc.identifier.issn	0009-9236
dc.identifier.uri	https://farfar.pharmacy.bg.ac.rs/handle/123456789/5300
dc.description.abstract	We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype.
dc.publisher	John Wiley and Sons Inc
dc.rights	restrictedAccess
dc.source	Clinical Pharmacology and Therapeutics
dc.title	What is the Current Clinical Impact of the CYP2CTG Haplotype?
dc.type	contributionToPeriodical
dc.rights.license	ARR
dc.citation.volume	115
dc.citation.issue	2
dc.citation.spage	183
dc.citation.epage	183
dc.identifier.wos	001107388700001
dc.identifier.doi	10.1002/cpt.3094
dc.identifier.pmid	37984075
dc.identifier.scopus	2-s2.0-85177230656
dc.type.version	publishedVersion